<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="124209">
  <!-- This xml conforms to an XML Schema at:
    http://clinicaltrials.gov/ct2/html/images/info/public.xsd
 and an XML DTD at:
    http://clinicaltrials.gov/ct2/html/images/info/public.dtd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on June 04, 2014</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>http://clinicaltrials.gov/show/NCT01685073</url>
  </required_header>
  <id_info>
    <org_study_id>NA_00068969</org_study_id>
    <nct_id>NCT01685073</nct_id>
  </id_info>
  <brief_title>The Role of Sleep in the Treatment of Cannabis Use Disorders</brief_title>
  <official_title>The Role of Sleep in the Treatment of Cannabis Use Disorders</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Johns Hopkins University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Johns Hopkins University</source>
  <oversight_info>
    <authority>United States: Food and Drug Administration</authority>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The number of people seeking treatment for marijuana-related problems is on the rise, yet
      there is no currently accepted medication proven to help them quit. Frequent marijuana users
      have reported that they have trouble sleeping when they try to quit, and that the loss of
      sleep can lead to relapse. This research is designed to measure the severity of sleep
      problems in people as they are trying to quit heavy use of marijuana, and to investigate
      whether extended-release zolpidem (Ambien CRÂ®) can improve quit rates among people trying to
      stop using marijuana.
    </textblock>
  </brief_summary>
  <overall_status>Recruiting</overall_status>
  <start_date>September 2012</start_date>
  <completion_date type="Anticipated">September 2015</completion_date>
  <primary_completion_date type="Anticipated">June 2015</primary_completion_date>
  <phase>Phase 2/Phase 3</phase>
  <study_type>Interventional</study_type>
  <study_design>Allocation: Randomized, Endpoint Classification: Efficacy Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Treatment</study_design>
  <primary_outcome>
    <measure>Sleep Efficiency</measure>
    <time_frame>up to 24 Weeks</time_frame>
    <safety_issue>No</safety_issue>
    <description>Sleep will be objectively measured at 5 time points during the study assessment period using ambulatory polysomnography (PSG) equipment.</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Cannabis Abstinence</measure>
    <time_frame>Twice weekly on Weeks 1-12; Week 24 and 36</time_frame>
    <safety_issue>No</safety_issue>
    <description>Urine drug testing will determine whether study participants are abstinent from cannabis use throughout participation in treatment (12 weeks) and at 3- and 6-month follow-up assessments</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Drug Addiction</condition>
  <arm_group>
    <arm_group_label>Zolpidem</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Participants receive active zolpidem nightly in addition to psychosocial therapy during 12-week treatment of a cannabis use disorder</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>Participants receive placebo medication during a 12-week psychosocial treatment for a cannabis use disorder</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Zolpidem extended-release</intervention_name>
    <description>nightly administration of zolpidem extended-release</description>
    <arm_group_label>Zolpidem</arm_group_label>
    <other_name>Ambien CR</other_name>
  </intervention>
  <intervention>
    <intervention_type>Behavioral</intervention_type>
    <intervention_name>MET/CBT</intervention_name>
    <description>a standardized 12-week therapy consisting of motivational enhancement therapy (MET) and cognitive behavior therapy (CBT) for treating cannabis use disorders will be administered to all study participants</description>
    <arm_group_label>Zolpidem</arm_group_label>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          1. Age 18-55 years.

          2. Recent problematic use of cannabis

          3. Cannabis use impacts sleep

        Exclusion Criteria:

          1. Dependent on drugs other than cannabis or nicotine, or current Axis I psychiatric
             disorder

          2. Moderate sleep apnea or periodic limb movement disorder

          3. Pregnant, breast feeding, or planning to become pregnant within the next 3 months

          4. Current condition associated with severe cognitive/social impairment

          5. Allergy to any ingredient in extended-release zolpidem or prior adverse reaction to
             zolpidem

          6. Current use of drugs that affect metabolism via cytochrome P450 or current illness
             resulting in severe hepatic impairment

          7. Current use of hypnotic medications
      </textblock>
    </criteria>
    <gender>Both</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>55 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Ryan Vandrey, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Johns Hopkins University</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Eva Lenoir</last_name>
    <phone>410-550-1929</phone>
    <email>elenoir1@jhmi.edu</email>
  </overall_contact>
  <location>
    <facility>
      <name>Johns Hopkins University</name>
      <address>
        <city>Baltimore</city>
        <state>Maryland</state>
        <zip>21224</zip>
        <country>United States</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Eva Lenoir</last_name>
      <phone>410-550-1929</phone>
      <email>elenoir1@jhmi.edu</email>
    </contact>
    <investigator>
      <last_name>Ryan Vandrey, PhD</last_name>
      <role>Principal Investigator</role>
    </investigator>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>December 2013</verification_date>
  <lastchanged_date>December 3, 2013</lastchanged_date>
  <firstreceived_date>September 11, 2012</firstreceived_date>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Johns Hopkins University</investigator_affiliation>
    <investigator_full_name>Ryan Vandrey</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>marijuana</keyword>
  <keyword>cannabis</keyword>
  <keyword>treatment</keyword>
  <keyword>insomnia</keyword>
  <keyword>relapse</keyword>
  <is_fda_regulated>Yes</is_fda_regulated>
  <is_section_801>Yes</is_section_801>
  <has_expanded_access>No</has_expanded_access>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Marijuana Abuse</mesh_term>
    <mesh_term>Substance-Related Disorders</mesh_term>
    <mesh_term>Behavior, Addictive</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm  -->
    <mesh_term>Zolpidem</mesh_term>
  </intervention_browse>
  <!-- Results have not yet been posted for this study                                -->
</clinical_study>
